|
BNIP3L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.86550999999868E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.09789999999965E-05 |
| Normal-vs-Stage2 |
3.899100E-03 |
| Normal-vs-Stage3 |
1.248540E-04 |
| Normal-vs-Stage4 |
1.61022999999316E-05 |
| Stage1-vs-Stage2 |
7.326400E-01 |
| Stage1-vs-Stage3 |
9.586400E-01 |
| Stage1-vs-Stage4 |
2.644600E-01 |
| Stage2-vs-Stage3 |
7.286600E-01 |
| Stage2-vs-Stage4 |
2.493200E-01 |
| Stage3-vs-Stage4 |
3.135200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.6064999999974E-05 |
| Normal-vs-AfricanAmerican |
9.457500E-02 |
| Normal-vs-Asian |
3.59699999999963E-05 |
| Caucasian-vs-AfricanAmerican |
2.685000E-01 |
| Caucasian-vs-Asian |
2.946200E-01 |
| AfricanAmerican-vs-Asian |
9.910400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.626300E-04 |
| Normal-vs-Female |
3.97649999994698E-06 |
| Male-vs-Female |
3.228400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.370000E-04 |
| Normal-vs-Age(41-60Yrs) |
2.61710000004634E-06 |
| Normal-vs-Age(61-80Yrs) |
1.963230E-04 |
| Normal-vs-Age(81-100Yrs) |
4.874800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.404000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.932400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.261800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.727800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.592800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.531000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.716800E-01 |
| Classical-VS-Follicular |
1.065440E-01 |
| Classical-VS-Other |
2.598800E-01 |
| Classical-VS-Normal |
2.405000E-04 |
| Tall-VS-Follicular |
5.945800E-01 |
| Tall-VS-Other |
3.896800E-01 |
| Tall-VS-Normal |
4.139500E-03 |
| Follicular-VS-Other |
6.249800E-01 |
| Follicular-VS-Normal |
9.85329999999562E-05 |
| Other-VS-Normal |
9.558600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.55410000000278E-05 |
| Normal-vs-N1 |
2.11989999999718E-05 |
| N0-vs-N1 |
3.691400E-01 |
|
|
